Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Xpovio (selinexor) was approved for adults with multiple myeloma who have received at least one prior therapy.
The SADAL study showed a 29% response rate for treatment-experienced people with DLBCL.
Study focused on people who have exhausted available therapies but want to continue with treatment.
First nuclear export inhibitor gets the nod for patients lacking treatment options.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.